Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mochuan Liu, Yuanjia Wang, Haoda Fu & Donglin Zeng. (2023) Controlling Cumulative Adverse Risk in Learning Optimal Dynamic Treatment Regimens. Journal of the American Statistical Association 0:0, pages 1-12.
Read now
Read now
Xiaolei Lin & Yuan Ji. (2020) The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials. Journal of Biopharmaceutical Statistics 30:6, pages 993-1005.
Read now
Read now
Fumihiro Takahashi & Satoshi Morita. (2018) Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial. Journal of Biopharmaceutical Statistics 28:5, pages 870-883.
Read now
Read now
Thomas A. Murray, Ying Yuan & Peter F. Thall. (2018) A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. Journal of the American Statistical Association 113:523, pages 1255-1267.
Read now
Read now
Yuanjia Wang, Haoda Fu & Donglin Zeng. (2018) Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. Journal of the American Statistical Association 113:521, pages 1-13.
Read now
Read now
Thomas A. Murray, Peter F. Thall, Ying Yuan, Sarah McAvoy & Daniel R. Gomez. (2017) Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer. Journal of the American Statistical Association 112:517, pages 11-23.
Read now
Read now
Yanxun Xu, Peter Müller, Abdus S. Wahed & Peter Thall. (2016) Rejoinder. Journal of the American Statistical Association 111:515, pages 948-950.
Read now
Read now
Articles from other publishers (32)
Shuying Zhu, Weining Shen, Haoda Fu & Annie Qu. (2024) Risk-aware restricted outcome learning for individualized treatment regimes of schizophrenia. The Annals of Applied Statistics 18:2.
Crossref
Crossref
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal & Xiongbin Lu. (2024) Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical Trials.
Crossref
Crossref
Steffen Ventz & Lorenzo Trippa. (2024) Bayesian Multi-Arm De-Intensification Designs. Bayesian Analysis -1:-1.
Crossref
Crossref
Ruizhe Chen & Chen Hu. 2024. Comprehensive Precision Medicine. Comprehensive Precision Medicine
283
292
.
Zhen Li, Jie Chen, Eric Laber, Fang Liu & Richard Baumgartner. (2023) Optimal Treatment Regimes: A Review and Empirical Comparison. International Statistical Review 91:3, pages 427-463.
Crossref
Crossref
Susan Halabi & Codruta Chiuzan. (2023) Randomized Phase I Trials — One Size Fits All?. NEJM Evidence 2:12.
Crossref
Crossref
Peter F. Thall, Yong Zang, Andrew G. Chapple, Ying Yuan, Ruitao Lin, David Marin & Pavlos Msaouel. (2023) Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clinical Cancer Research 29:22, pages 4549-4554.
Crossref
Crossref
Indrabati Bhattacharya, Ashkan Ertefaie, Kevin G Lynch, James R McKay & Brent A Johnson. (2023) Nonparametric Bayesian Q-learning for optimization of dynamic treatment regimes in the presence of partial compliance. Statistical Methods in Medical Research 32:9, pages 1649-1663.
Crossref
Crossref
Ruitao Lin, Haolun Shi, Guosheng Yin, Peter F. Thall, Ying Yuan & Christopher R. Flowers. (2022) Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials. The Annals of Applied Statistics 16:4.
Crossref
Crossref
Apostolia M. Tsimberidou, Peter Müller & Yuan Ji. (2022) Innovative trial design in precision oncology. Seminars in Cancer Biology 84, pages 284-292.
Crossref
Crossref
Xingde Duan, Zhenhuan Wu, Shi Zhang & Wenzhuan Zhang. (2022) Modeling Heterogeneity in the Assessment of Treatment Effects on Tumor Development While Accounting for Monotone Dropout. Bulletin of the Malaysian Mathematical Sciences Society 45:S1, pages 37-48.
Crossref
Crossref
Juhee Lee, Peter F. Thall & Pavlos Msaouel. (2021) Precision Bayesian phase I‐II dose‐finding based on utilities tailored to prognostic subgroups. Statistics in Medicine 40:24, pages 5199-5217.
Crossref
Crossref
Pavlos Msaouel, Juhee Lee & Peter F. Thall. (2021) Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers 13:11, pages 2741.
Crossref
Crossref
Junyao Wang, Liwen Wu & Abdus S. Wahed. (2021) Adaptive randomization in a two-stage sequential multiple assignment randomized trial. Biostatistics.
Crossref
Crossref
Haolun Shi, Jiguo Cao, Ying Yuan & Ruitao Lin. (2021) uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials. Statistics in Medicine 40:11, pages 2626-2649.
Crossref
Crossref
Peter F. Thall. (2021) Adaptive Enrichment Designs in Clinical Trials. Annual Review of Statistics and Its Application 8:1, pages 393-411.
Crossref
Crossref
Ruitao LinPeter F. ThallYing Yuan. (2021) A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis 16:1.
Crossref
Crossref
Xiaolei Lin & Yuan Ji. (2020) Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology. Statistical Methods in Medical Research 30:3, pages 843-856.
Crossref
Crossref
Xinyang Huang & Jin Xu. (2020) Estimating individualized treatment rules with risk constraint. Biometrics 76:4, pages 1310-1318.
Crossref
Crossref
Andrew G. Chapple & Peter F. Thall. (2020) Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteria. Contemporary Clinical Trials 97, pages 106099.
Crossref
Crossref
Ruitao Lin, Peter F. Thall & Ying Yuan. (2019) An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes. Biometrics 76:1, pages 304-315.
Crossref
Crossref
Peter F. Thall. (2020) Bayesian cancer clinical trial designs with subgroup-specific decisions. Contemporary Clinical Trials 90, pages 105860.
Crossref
Crossref
Peter F. Thall. (2019) Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials. JCO Precision Oncology:3, pages 1-7.
Crossref
Crossref
Revathi Ananthakrishnan, Stephanie Green, Daniel Li & Michael LaValley. (2019) 2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy. Contemporary Clinical Trials Communications 16, pages 100461.
Crossref
Crossref
Jiaying LyuEmily CurranYuan Ji. (2018) Bayesian Adaptive Design for Finding the Maximum Tolerated Sequence of Doses in Multicycle Dose-Finding Clinical Trials. JCO Precision Oncology:2, pages 1-19.
Crossref
Crossref
F. Yan, P.F. Thall, K.H. Lu, M.R. Gilbert & Y. Yuan. (2018) Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding. Annals of Oncology 29:3, pages 694-699.
Crossref
Crossref
Elizabeth Garrett-Mayer & Nathaniel O’Connell. 2018. Novel Designs of Early Phase Trials for Cancer Therapeutics. Novel Designs of Early Phase Trials for Cancer Therapeutics
17
32
.
Yanxun Xu, Peter F. Thall, Peter Müller & Mehran J. Reza. (2017) A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling. Bayesian Analysis 12:3.
Crossref
Crossref
Eric B Laber & Marie Davidian. (2017) Dynamic treatment regimes, past, present, and future: A conversation with experts. Statistical Methods in Medical Research 26:4, pages 1605-1610.
Crossref
Crossref
Daniel H. Li, James B. Whitmore, Wentian Guo & Yuan Ji. (2017) Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials. Clinical Cancer Research 23:1, pages 13-20.
Crossref
Crossref
Hiroyuki Sato, Akihiro Hirakawa & Chikuma Hamada. (2016) An adaptive dose‐finding method using a change‐point model for molecularly targeted agents in phase I trials. Statistics in Medicine 35:23, pages 4093-4109.
Crossref
Crossref
Juhee Lee, Peter F. Thall, Yuan Ji & Peter Müller. (2016) A decision-theoretic phase I–II design for ordinal outcomes in two cycles. Biostatistics 17:2, pages 304-319.
Crossref
Crossref